KLRK1 and neoplasm: In NKG2D knockout mice, QBKPN administration failed to reduce lung tumor burden relative to placebo-treated mice (Fig. 5D), confirming the requirement of NK cell-mediated anti-tumor efficacy through the NKG2D pathway.